Skip to content

Keros Therapeutics, Inc.

KROS

CIK 0001664710

← back to feed
Revenue (TTM)
$244.04M
+6,775.0% YoY Q1 May 2026
Net Income (TTM)
$86.77M
+146.4% YoY Q1 May 2026
EPS Diluted (TTM)
$1.47
+146.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
29.1%
Q1 May 2026
Net Margin
35.6%
Q1 May 2026
Free Cash Flow (TTM)
$76.2M
Q1 May 2026
Cash
$281.5M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
19.79M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings